Two potential mechanisms of action for suppressing SARS-CoV-2-replication and spread in airway epithelium are revealed by this study:Treatment with the B2R-antagonist led to a downregulation of the viral entry receptor ACE2, in vitro in primary airway epithelial cells and in vivo in a murine airway inflammation model. This evidence concerns the gene ACE2 and inflammation.